SSY GROUP (02005.HK): Choline Fenofibrate Sustained-release Capsule Obtains Drug Production Registration Approval
NewTimeSpace News: SSY Group (02005.HK) released a voluntary announcement on 16 July 2026. The Group has secured the drug production registration approval from the National Medical Products Administration (NMPA) for Choline Fenofibrate Sustained-release Capsule (135mg). As a Category 4 chemical drug, it is deemed to have passed generic consistency evaluation.
On the basis of dietary control for adult patients, the product is indicated for lowering triglyceride levels in patients with severe hypertriglyceridemia, as well as treating patients with primary hypercholesterolemia or mixed dyslipidaemia.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
- SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
- SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
- SSY Group (02005.HK): Trustee Acquires 1 Million Shares Under Restricted Share Incentive Scheme
- SSY GROUP(02005.HK): Trustee Purchases 2 Million Shares Under Restricted Share Award Scheme at Average Price of HK$2.1585
